Related Experiment Video

Updated: Aug 7, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

[Angiotensin II induced cardiac hypertrophy is blocked by PTEN via suppressing Ca2+/Calcineurin pathway]

Lin-jun Yu1, Shan-jun Zhu, Yi-zhong Zhou

  • 1Department of Cardiology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China.

Zhonghua Xin Xue Guan Bing Za Zhi
|July 18, 2006
PubMed
Abstract

Insights

Overexpressing PTEN protein in cardiomyocytes blocks Angiotensin II-induced cardiac hypertrophy by inhibiting the calcium/Calcineurin pathway, offering a potential therapeutic target.

Area of Science:

  • Molecular cardiology
  • Cell signaling pathways
  • Cardiac hypertrophy research

Context:

  • Cardiac hypertrophy is a significant risk factor for heart failure.
  • The Angiotensin II (Ang II) signaling pathway plays a crucial role in cardiac remodeling.
  • The Ca(2+)/Calcineurin pathway is implicated in the development of cardiac hypertrophy.

Purpose:

  • To investigate the role of PTEN (Phosphatase and tensin homolog) in Ang II-induced cardiomyocyte hypertrophy.
  • To examine the impact of PTEN on the Ca(2+)/Calcineurin signaling pathway in cardiomyocytes.

Summary:

  • Neonatal rat cardiomyocytes were treated with adenovirus encoding PTEN (Ad-PTEN-GFP) or a control (Ad-GFP) before stimulation with Ang II.
  • PTEN overexpression significantly reduced Ang II-induced increases in intracellular calcium ([Ca(2+)] i), CaNAbeta mRNA and protein levels, and calcineurin phosphatase activity.
  • Conversely, Ang II stimulation upregulated these markers in control cardiomyocytes.

Impact:

  • PTEN overexpression effectively inhibits Ang II-induced cardiac hypertrophy.
  • This inhibition occurs through the suppression of the Ca(2+)/Calcineurin pathway.
  • PTEN represents a potential therapeutic target for managing cardiac hypertrophy.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...